Efficacy and economics of targeted panel versus whole-exome sequencing in 878 patients with suspected primary immunodeficiency

CD Platt, F Zaman, W Bainter, K Stafstrom… - Journal of Allergy and …, 2021 - Elsevier
Background Next-generation sequencing has become a first-line tool for the diagnosis of
primary immunodeficiency. However, patient access remains limited because of restricted …
被引用次数：42 相关文章

Efficacy and economics of targeted panel versus whole-exome sequencing in 878 patients with suspected primary immunodeficiency

CD Platt, F Zaman, W Bainter, K Stafstrom… - Journal of Allergy and …, 2021 - jacionline.org
Background Next-generation sequencing has become a first-line tool for the diagnosis of
primary immunodeficiency. However, patient access remains limited because of restricted …

Efficacy and economics of targeted panel versus whole-exome sequencing in 878 patients with suspected primary immunodeficiency

CD Platt, F Zaman, W Bainter… - The Journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Next-generation sequencing has become a first-line tool for the diagnosis of
primary immunodeficiency. However, patient access remains limited because of restricted …
[HTML] nih.gov

[HTML][HTML] Efficacy and economics of targeted panel versus whole exome sequencing in 878 patients with suspected primary immunodeficiency

CD Platt, F Zaman, W Bainter, K Stafstrom… - The Journal of allergy …, 2021 - ncbi.nlm.nih.gov
Background NGS has become a first-line tool for diagnosis of PID. However, patient access
remains limited due to restricted insurance coverage and a lack of guidelines addressing …

[引用][C] Efficacy and economics of targeted panel versus whole-exome sequencing in 878 patients with suspected primary immunodeficiency

CD Platt, F Zaman, W Bainter, K Stafstrom… - Journal of Allergy and …, 2021 - cir.nii.ac.jp
Efficacy and economics of targeted panel versus whole-exome sequencing in 878 patients
with suspected primary immunodeficiency | CiNii Research CiNii 国立情報学研究所 学術情報 …

Efficacy and economics of targeted panel versus whole-exome sequencing in 878 patients with suspected primary immunodeficiency.

CD Platt, F Zaman, W Bainter, K Stafstrom… - The Journal of Allergy …, 2020 - europepmc.org
Background Next-generation sequencing has become a first-line tool for the diagnosis of
primary immunodeficiency. However, patient access remains limited because of restricted …

Efficacy and economics of targeted panel versus whole-exome sequencing in 878 patients with suspected primary immunodeficiency

CD Platt, F Zaman, W Bainter, K Stafstrom… - Journal of Allergy and …, 2021 - jacionline.org
Background Next-generation sequencing has become a first-line tool for the diagnosis of
primary immunodeficiency. However, patient access remains limited because of restricted …